Arris CEO named to Signal Pharmaceuticals' board.SAN DIEGO--(BUSINESS WIRE)--June 14, 1995--Signal Pharmaceuticals Inc., a biopharmaceutical company focused on the discovery and development of small-molecule drugs that regulate gene expression for the treatment of inflammatory, viral and neurologic diseases, Wednesday announced that John P. Walker, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Arris ar·ris n. pl. arris or ar·ris·es The sharp edge or ridge formed by two surfaces meeting at an angle, as in a molding. [Alteration of Old French areste, fishbone, spine Pharmaceutical Corp., will join its board of directors. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Alan J. Lewis, Ph.D., president: "John's knowledge of emerging companies, as well as his experience in leading a large corporation, will be tremendous assets as we build our company. He has enjoyed tremendous success forming corporate collaborations with pharmaceutical companies around the world. "We are looking to him and our other directors to share their visions about Signal as we target transcription factors as a way to control disease." Walker joined South San Francisco-based Arris in 1993 and has guided the company through its initial public offering, collaborative agreements with Amgen, Pharmacia and Bayer, and continuance of an integrated approach to structure-based drug design aimed at the discovery and development of synthetic, small-molecule therapeutics. Prior to his position at Arris, Walker was a venture capitalist Venture Capitalist An investor who provides capital to either start-up ventures or support small companies who wish to expand but do not have access to public funding. Notes: Venture capitalists usually expect higher returns for the additional risks taken. with Alpha Venture Partners, a seed-stage fund focused on the life sciences. In that role, he served as chairman of two of the firm's portfolio companies and director of a third. Previously, he was chairman, president and CEO of Vitaphore Corp., a Redwood City Redwood City, city (1990 pop. 66,072), seat of San Mateo co., W Calif., on San Francisco Bay; inc. 1868. Manufactures include commmunications, electrical, electronic, and medical equipment. , Calif.-based materials science materials science Study of the properties of solid materials and how those properties are determined by the material's composition and structure, both macroscopic and microscopic. company engaged in developing and commercializing products in the critical-care, ophthalmic, wound-care and cardiovascular markets, until it was acquired by Union Carbide Union Carbide Corporation (Union Carbide) is one of the oldest chemical and polymers companies in the United States, and currently has more than 3,800 employees. Chemicals and Plastics Co. Walker began his career at American Hospital Corp., where he held increasingly responsible management positions, ultimately serving as president of the corporation's Hospital Co., a $1.5 billion distributor of medical surgical supplies. He is a graduate of the State University of New York (body) State University of New York - (SUNY) The public university system of New York State, USA, with campuses throughout the state. at Buffalo and has conducted graduate business studies at the Columbia School of Marketing, the Wharton School of Finance, and the Northwestern University Institute of Management. In addition to Lewis and chairman Patrick F. Latterell of Venrock Associates, Signal's board includes Brook H. Byers of Kleiner Perkins Caufield & Byers; Luke B. Evnin, Ph.D., of Accel Partners; Arnold Oronsky, Ph.D., of Interwest Partners; and Harry F. Hixson, Ph.D., former president of Amgen. Signal Pharmaceuticals is pioneering the discovery and development of small-molecule therapeutics which regulate the transcription factors involved in the progression of a number of inflammatory, viral and neurologic diseases. The core technology for the company's research was discovered in the laboratories of its three founders and has been licensed from the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). and the Salk Institute. CONTACT: Signal Pharmaceuticals Inc., San Diego Alan J. Lewis, 619/558-7500 or Keatinge & Associates Inc. Richard W. Keatinge, 619/625-2100 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion